8-K: Agenus Q3 2025: BOT/BAL Gains French Access, Phase 3 On Track

Agenus Inc. reported strong Q3 2025 results, highlighted by French government-funded access for BOT/BAL, positive long-term survival data, and the initiation of a global Phase 3 trial.

Summary

• France's medicines agency (ANSM) authorized reimbursed compassionate access (AAC) for botensilimab plus balstilimab (BOT/BAL) in refractory MSS mCRC without active liver metastases, marking the first government-funded access for this population.
• BOT/BAL achieved 42% two-year overall survival (OS) and 20.9-month median OS in 123 heavily pretreated MSS mCRC patients without active liver metastases, exceeding median OS benchmarks of 8-14 months with current standards of care.
• Updated Phase 1b results in over 400 patients demonstrated 39% two-year OS across more than five refractory cancers, including colorectal, ovarian, sarcoma, lung, and hepatocellular tumors, with responses seen after prior checkpoint inhibitor failure.
• The global registrational Phase 3 BATTMAN trial, evaluating BOT/BAL versus best supportive care in refractory, unresectable MSS/pMMR colorectal cancer, is launching in Q4 2025 across 100+ sites in Canada, France, Australia, and New Zealand.
• Agenus and Zydus agreed to a $10 million bridge facility in October, ahead of an anticipated $91 million upon closing of a transaction which also includes an equity investment at $7.50 per share.
• The deconsolidation of MiNK in July 2025, due to Agenus ownership falling below 50%, generated approximately a $100.9 million gain, resulting in net income for the three-month and nine-month period ended September 30, 2025.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for BOT/BAL, including superior survival rates compared to standard of care in a difficult-to-treat population, and significant regulatory progress with reimbursed access in France. The initiation of a global Phase 3 trial and a substantial financial transaction with Zydus further bolster a very positive outlook, despite the inherent risks of drug development.

Positives

• French government-funded, reimbursed compassionate access (AAC) granted for BOT/BAL in refractory MSS mCRC, marking the first such access by a regulatory agency.
• BOT/BAL demonstrated superior two-year overall survival (42%) and median OS (20.9 months) in heavily pretreated MSS mCRC patients without active liver metastases, significantly exceeding standard of care benchmarks of 8-14 months.
• Updated Phase 1b results showed durable 39% two-year OS across over 400 patients with more than five refractory cancers, including responses after prior checkpoint inhibitor failure.
• Initiation of the global registrational Phase 3 BATTMAN trial in Q4 2025, indicating progress towards potential market approval.
• A $10 million bridge facility from Zydus and an anticipated $91 million upon transaction closing, including an equity investment at $7.50 per share, strengthens financial position.
• A $100.9 million gain from MiNK deconsolidation contributed to net income for Q3 2025.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, as described in the company's most recent Annual Report on Form 10-K for 2024 and subsequent Quarterly Reports on Form 10-Q.

Future Outlook

Patient enrollment for the BATTMAN Phase 3 trial is expected to commence before year-end 2025. Data updates from investigator-initiated neoadjuvant and frontline trials are anticipated in the first half of 2026. The French AAC program will also generate real-world evidence for BOT/BAL.

Management Comments

• Agenus is dedicated to making investigational medicines available to patients with cancer at the appropriate time and in the correct manner.
• The company aims to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies, and adjuvants.

Industry Context

The immuno-oncology field continues to seek effective treatments for refractory cancers, particularly those unresponsive to standard checkpoint inhibitors. Agenus's BOT/BAL combination, targeting CTLA-4 and PD-1, addresses this critical unmet need by demonstrating durable responses in 'cold tumors' and heavily pretreated patient populations, potentially expanding the reach of immunotherapy beyond current limitations. The initiation of a global Phase 3 trial and government-funded access in France position Agenus as a significant player in developing next-generation cancer immunotherapies.

Comparison to Industry Standards

• BOT/BAL's 20.9-month median overall survival (OS) in heavily pretreated MSS mCRC patients without active liver metastases significantly surpasses the 8-14 months median OS typically observed with current standards of care in the third-line-plus setting.
• The demonstration of responses after prior checkpoint inhibitor failure in a pantumor cohort of over 400 patients highlights BOT/BAL's potential to treat patients who have exhausted other immunotherapy options, a challenging segment for many existing treatments.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, regulatory progress, initiation of a registrational trial, and a significant financial transaction, potentially increasing company valuation and future revenue prospects.
• Patients: Significant positive impact, as BOT/BAL offers a new, potentially more effective treatment option for refractory cancers, including government-funded access in France.
• Healthcare Providers: Provides a new therapeutic option for challenging cancer cases, supported by strong clinical data.
• Employees: Positive outlook due to company progress and potential for future growth.

Next Steps

• BATTMAN patient enrollment to commence before year-end 2025.
• Continue BOT/BAL paid access programs in France and other European countries/regions.
• Expect neoadjuvant and frontline data updates from investigator-initiated trials in 1H 2026.
• Generate real-world evidence from the France AAC program.
• Host a Stakeholder Briefing Webcast in late November.

Key Dates

Recommendation

The filing provides compelling evidence of BOT/BAL's clinical efficacy, demonstrating superior overall survival rates compared to current standards of care in heavily pretreated, refractory cancer patients. The successful securing of government-funded reimbursed access in France is a significant regulatory and commercial milestone, validating the drug's potential. The initiation of a global Phase 3 registrational trial signals clear progress towards market approval, and the substantial financial transaction with Zydus further strengthens the company's balance sheet. These factors collectively indicate a strong growth trajectory and significant upside potential for Agenus, making it a 'strong buy' for investors.

Keywords

Agenus, BOT/BAL, Botensilimab, Balstilimab, Immuno-oncology, Cancer immunotherapy, MSS mCRC, Colorectal cancer, Refractory cancer, Phase 3 trial, BATTMAN, Clinical trials, Regulatory approval, France ANSM, Zydus, MiNK Therapeutics, Oncology, Biotechnology